Insulet price target raised to $342 from $300 at Stifel

Stifel analyst Mathew Blackman raised the firm’s price target on Insulet to $342 from $300 and keeps a Hold rating on the shares. While stating that Insulet has "undeniable" U.S. commercial momentum and added potential growth catalysts ahead, the firm believes U.S. market share gains through 2024 are already baked into the current valuation. The firm’s increased target reflects the positive outputs of its just-published U.S. Insulin Pump Survey, but its expectation is for a "minimal multiple expansion opportunity" for Insulet.